Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle
® to improve NAFLD and the metabolic syndrome.
Ingestion of Femarelle will improve non alcoholic steatohepatitis and the metabolic syndrome
in patients suffering from these conditions.
Subjects will receive treatment with Femarele 530 mg (1 capsule twice a day) for 90 days and
will then be monitored off study treatment for an additional 4 weeks.